TrialAlzheimer's research & therapy2024

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.

Hua Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.